Adaptimmune Therapeutics : Company Presentation of Data at ASCO 2021 Annual Meeting- PDF

SPEARHEAD-1 Data at ASCO 2021 Annual Meeting May 19, 2021

Disclaimer

This presentation contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect" and other words of similar meaning. These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials; our ability to submit an IND and successfully advance our technology platform to improve the safety and effectiveness of our existing TCR therapeutic candidates; the rate and degree of market acceptance of T-cell therapy generally and of our TCR therapeutic candidates; government regulation and approval, including, but not limited to, the expected regulatory approval timelines for TCR therapeutic candidates; and our ability to protect our proprietary technology and enforce our intellectual property rights; amongst others. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 6, 2021 and our other SEC filings.

We urge you to consider these factors carefully in evaluating the forward-looking statements herein and you are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. The forward-looking statements contained in this presentation speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.

We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.

2

Our vision and mission

Arming Cells.

Against Cancer.

For Good.

To transform the lives of people with cancer by designing and delivering cell therapies

3

5-year core value drivers: our "2-2-5-2" plan

Data from SPEARHEAD-1 will support our BLA filing next year for our first commercial MAGE-A4 targeted product

Two	Two	Five	Two
marketed	additional BLAs	autologous	allogeneic
SPEAR T-cell	for SPEAR T-cell	products in the	products entering
products targeting	products	clinic	the clinic
MAGE-A4

	•	Synovial sarcoma		•	Additional indications	•	HiT
					for MAGE-A4	•	Next-gen TILs
	•	Esophageal and
		EGJ cancers	•	targeted products	•	New targets
				ADP-A2AFP	•	Broader HLA

coverage

• SPEAR T-cell product targeting MAGE-A4
• HiT mesothelin - partnered with Astellas

Integrated Cell Therapy Capabilities

Research | Preclinical | Translational | Clinical | CMC | Regulatory | Commercial

EGJ: esophagogastric junction cancer; HiT: HLA-independentT-cell

4 receptor (TCR); TIL: tumor infiltrating lymphocyte; CMC: chemistry, manufacturing, and controls

There is a large unmet medical need for people with synovial sarcoma

"Initial data from SPEARHEAD-1 indicate that afami-	"Amongst the limitations of using chemotherapy to
cel has the potential to offer people with synovial	treat synovial sarcoma is the need to always be on a
sarcoma a promising new treatment option where	therapy and to deal with the side effects that come
there is currently a great unmet medical need. As	from it. Chemo patients are not able to live a normal
clinicians, we want to be able to provide a treatment	life. What we're really looking for is a therapy where
regimen that can help offer a better quality of life."	once it's performed, it's durable and you don't need
-- Dr. Sandra P. D'Angelo of the	another one."
-- Dr. Brian Van Tine, Associate Professor of Medicine,
Memorial Sloan Kettering Cancer Center
	Division of Oncology, Section of Medical Oncology,
	Washington University School of Medicine

"After suffering from misdiagnosis or years long journey

to diagnosis, people living with synovial sarcoma struggle with limited, and often ineffective, treatment options. A treatment for synovial sarcoma patients that gives them more options, a better prognosis, and a better quality of life is long overdue."

-- Brandi Felser, CEO, Sarcoma Foundation of America

5